XML 20 R9.htm IDEA: XBRL DOCUMENT
v3.25.1

REVENUES | 3 Months Ended
--- | ---
Mar. 31, 2025
Revenue from Contract with Customer [Abstract] |
REVENUES | REVENUES The Company’s revenues by segment and by payers/customer groups were as follows:
| Three Months Ended March 31, 2025 |  | Three Months Ended March 31, 2024
| North America |  | Europe |  | Other |  | Total |  | North America |  | Europe |  | Other |  | Total
Payer/Customer |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Dx |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clients | 24 | % |  | — | % |  | — | % |  | 24 | % |  | 25 | % |  | — | % |  | — | % |  | 25 | %
Patients | 10 | % |  | — | % |  | — | % |  | 10 | % |  | 10 | % |  | — | % |  | — | % |  | 10 | %
Medicare and Medicaid | 8 | % |  | — | % |  | — | % |  | 8 | % |  | 8 | % |  | — | % |  | — | % |  | 8 | %
Third party | 36 | % |  | — | % |  | — | % |  | 36 | % |  | 35 | % |  | — | % |  | — | % |  | 35 | %
Total Dx revenues by payer | 78 | % |  | — | % |  | — | % |  | 78 | % |  | 78 | % |  | — | % |  | — | % |  | 78 | %
BLS |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pharmaceutical, biotechnology, and medical device companies | 9 | % |  | 9 | % |  | 4 | % |  | 22 | % |  | 9 | % |  | 9 | % |  | 4 | % |  | 22 | %
Total Revenues | 87 | % |  | 9 | % |  | 4 | % |  | 100 | % |  | 87 | % |  | 9 | % |  | 4 | % |  | 100 | %
Revenues in the United States (U.S.) were $2,813.8 (84.1%) and $2,654.6 (83.6%) for the three months ended March 31, 2025, and 2024, respectively. Accounts Receivable, Unbilled Services, and Unearned Revenue The following table provides information about accounts receivable, unbilled services, and unearned revenue from contracts with customers:
| March 31, 2025 |  | December 31, 2024
Dx accounts receivable | $ | 1,403.2 |  |  | $ | 1,259.3 |
BLS accounts receivable | 758.6 |  |  | 729.5 |
Less BLS allowance for credit losses | (38.6) |  |  | (44.7) |
Accounts receivable, net | $ | 2,123.2 |  |  | $ | 1,944.1 |
Gross unbilled services | $ | 158.8 |  |  | $ | 160.5 |
Less reserve for unbilled services | (7.5) |  |  | (7.6) |
Unbilled services | $ | 151.3 |  |  | $ | 152.9 |
Revenues recognized during the period that were included in the unearned revenue balance at the beginning of the period were $68.9 and $51.0 for the three months ended March 31, 2025, and 2024, respectively. Allowance for Credit Losses BLS estimates future expected credit losses on accounts receivable and unbilled services over the remaining collection period of the instrument. The rollforward for the allowance for credit losses is as follows:
| Accounts Receivable |  | Unbilled Services |  | Total
Allowance for credit losses at December 31, 2024 | $ | 44.7 |  |  | $ | 7.6 |  |  | $ | 52.3 |
Write offs | (6.8) |  |  | (0.2) |  |  | (7.0) |
Foreign currency impact | 0.7 |  |  | 0.1 |  |  | 0.8 |
Allowance for credit losses at March 31, 2025 | $ | 38.6 |  |  | $ | 7.5 |  |  | $ | 46.1 |

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration